Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
PLoS One ; 7(3): e33760, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22479438

RESUMO

The leaky, heterogeneous vasculature of human tumors prevents the even distribution of systemic drugs within cancer tissues. However, techniques for studying vascular delivery systems in vivo often require complex mammalian models and time-consuming, surgical protocols. The developing chicken embryo is a well-established model for human cancer that is easily accessible for tumor imaging. To assess this model for the in vivo analysis of tumor permeability, human tumors were grown on the chorioallantoic membrane (CAM), a thin vascular membrane which overlays the growing chick embryo. The real-time movement of small fluorescent dextrans through the tumor vasculature and surrounding tissues were used to measure vascular leak within tumor xenografts. Dextran extravasation within tumor sites was selectively enhanced an interleukin-2 (IL-2) peptide fragment or vascular endothelial growth factor (VEGF). VEGF treatment increased vascular leak in the tumor core relative to surrounding normal tissue and increased doxorubicin uptake in human tumor xenografts. This new system easily visualizes vascular permeability changes in vivo and suggests that vascular permeability may be manipulated to improve chemotherapeutic targeting to tumors.


Assuntos
Permeabilidade Capilar , Sistemas de Liberação de Medicamentos , Animais , Permeabilidade Capilar/efeitos dos fármacos , Linhagem Celular , Embrião de Galinha , Membrana Corioalantoide/irrigação sanguínea , Membrana Corioalantoide/patologia , Doxorrubicina/administração & dosagem , Azul Evans , Humanos , Interleucina-2/farmacologia , Microscopia , Neoplasias/irrigação sanguínea , Neoplasias/patologia , Neovascularização Patológica , Imagem com Lapso de Tempo , Transplante Heterólogo/patologia , Microambiente Tumoral , Fator A de Crescimento do Endotélio Vascular/farmacologia
2.
Nutr Res ; 31(7): 544-54, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21840471

RESUMO

The activity of lysine α-ketoglutarate reductase (LKR), the initial enzyme in the principal pathway of lysine catabolism, is a primary determinant of whole-body lysine status. Past research indicated that LKR activity was predominantly hepatic; recent in vivo data suggest that other tissues can also catabolize lysine. The hypothesis of this investigation was that lysine catabolism takes place in extrahepatic tissues in pigs and that the enzymes involved may be subject to inhibition or activation. Using mitochondria from various tissues of market-age pigs, the activities of LKR and saccharopine dehydrogenase were measured. Liver mitochondria had the highest LKR activity, and the enzyme was subject to substrate inhibition. Mitochondria from the muscle, kidney, heart, and intestinal epithelial cells all had measurable LKR activity. The LKR activity was significantly inhibited by a variety of compounds including saccharopine, α-aminoadipate, α-ketoadipate, 5-hydroxy-l-lysine, and several metals. Oxidation of (14)C-lysine to (14)CO(2) was demonstrated in mitochondria isolated from the liver, muscle, and intestinal epithelial cells. Western blotting confirmed the presence of the α-aminoadipate δ-semialdehyde synthase protein in some extrahepatic tissues. These data show a significant capacity for lysine degradation in these extrahepatic tissues, most notably in cells of the intestine and muscle. These tissues should be considered important contributors to whole-body lysine catabolism.


Assuntos
Mucosa Intestinal/enzimologia , Cetona Oxirredutases/metabolismo , Rim/enzimologia , Fígado/enzimologia , Lisina/metabolismo , Músculo Esquelético/enzimologia , Animais , Western Blotting , Inibidores Enzimáticos/farmacologia , Cetona Oxirredutases/antagonistas & inibidores , Mitocôndrias/enzimologia , Miocárdio/enzimologia , Oxirredução , Sacaropina Desidrogenases/metabolismo , Suínos
3.
J Leukoc Biol ; 82(6): 1575-84, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17724165

RESUMO

In Crohn's disease and ulcerative colitis patients, the numbers of neutrophils recovered from stool directly correlates with the severity of disease, implying that neutrophils in the lumen contribute to the tissue destruction; therefore, it is important to understand the mechanisms behind transintestinal epithelial migration. Neutrophil transintestinal epithelial migration to fMLP is appreciated to be CD11b/CD18 integrin (Mac-1)-dependent, while we recently reported that migration to C5a is Mac-1-independent. Here, we investigated whether phospholipase D (PLD), a signaling molecule linked to chemoattractant activation of neutrophils, is necessary for both Mac-1-dependent and Mac-1-independent migration. Both fMLP and C5a increased neutrophil expression of the Mac-1 activation epitope, indicating PLD was activated. This up-regulation was dose-dependently prevented by incubation of neutrophils in 1-butanol, an inhibitor of PLD activity. Despite this effect on Mac-1, 1-butanol did not prevent neutrophil migration across acellular filters. Incubation in 1-butanol did inhibit fMLP but not C5a-mediated migration across intestinal epithelial cell monolayers, showing that transepithelial migration to fMLP but not C5a is dependent on PLD. The addition of phosphatidic acid, a reaction product of PLD, partially restored fMLP-mediated transepithelial migration in the presence of 1-butanol but not the migration of Mac-1-deficient neutrophil-differentiated HL-60 cells. Thus PLD control over expression of the Mac-1 activation epitope is critical for neutrophil migration to fMLP but not C5a. Moreover, as PLD controls other neutrophil functions, such as the oxidative response, degranulation, and protease release, we could exclude these functions as being important in neutrophil transepithelial migration to C5a.


Assuntos
Movimento Celular/efeitos dos fármacos , Complemento C5a/farmacologia , Células Epiteliais/citologia , N-Formilmetionina Leucil-Fenilalanina/farmacologia , Neutrófilos/citologia , Neutrófilos/enzimologia , Fosfolipase D/metabolismo , 1-Butanol/farmacologia , Bucladesina/farmacologia , Antígeno CD11b/imunologia , Antígenos CD18/imunologia , Diferenciação Celular/efeitos dos fármacos , Fatores Quimiotáticos/farmacologia , Quimiotaxia/efeitos dos fármacos , Células Epiteliais/efeitos dos fármacos , Epitopos/imunologia , Células HL-60 , Humanos , Antígeno de Macrófago 1/imunologia , Modelos Imunológicos , Ácidos Fosfatídicos/metabolismo , Fosfolipase D/antagonistas & inibidores , Regulação para Cima/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA